Scholarlink

<p>β-Lactamases confer bacterial resistance by hydrolyzing β-lactam antibiotics. Klebsiella pneumoniae carbapenemases (KPCs) are a major cause of resistance to carbapenems, but combinations of β-lactams with β-lactamase inhibitors, such as ceftazidime/avibactam, initially restored activity against these enzymes. However, treatment has driven the emergence of KPC variants that evade inhibition. Here we investigate the evolutionary and mechanistic consequences of three clinically observed substitutions -D179Y, T243M and H274Y- that together convert the broad-spectrum KPC-2 enzyme into a variant specialized for ceftazidime/avibactam resistance. Using steady-state and pre-steady-state kinetic analyses with ceftazidime, cephalothin and imipenem, we show that T243M enhances cephalosporin hydrolysis, whereas H274Y modulates this effect. Introduction of D179Y decreases both <i>k</i><sub>cat</sub> and <i>K</i><sub>M</sub> and shifts the rate-limiting step of catalysis to deacylation. Together, these mutations act cooperatively, reducing catalytic efficiency while promoting resistance to ceftazidime/avibactam. These findings reveal how epistatic interactions shape the evolution of clinically relevant β-lactamase variants and may help anticipate future resistance trajectories and guide inhibitor design.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced catalytic activity of KPC β-lactamase can increase ceftazidime resistance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • André Birgy,
  • Dignite Fabrice Ngango,
  • Murugesan Palaniappan,
  • Shahlo O. Solieva,
  • Devin G. Kelly,
  • Zhizeng Sun,
  • Gregory Bowman,
  • Timothy Palzkill

摘要

β-Lactamases confer bacterial resistance by hydrolyzing β-lactam antibiotics. Klebsiella pneumoniae carbapenemases (KPCs) are a major cause of resistance to carbapenems, but combinations of β-lactams with β-lactamase inhibitors, such as ceftazidime/avibactam, initially restored activity against these enzymes. However, treatment has driven the emergence of KPC variants that evade inhibition. Here we investigate the evolutionary and mechanistic consequences of three clinically observed substitutions -D179Y, T243M and H274Y- that together convert the broad-spectrum KPC-2 enzyme into a variant specialized for ceftazidime/avibactam resistance. Using steady-state and pre-steady-state kinetic analyses with ceftazidime, cephalothin and imipenem, we show that T243M enhances cephalosporin hydrolysis, whereas H274Y modulates this effect. Introduction of D179Y decreases both kcat and KM and shifts the rate-limiting step of catalysis to deacylation. Together, these mutations act cooperatively, reducing catalytic efficiency while promoting resistance to ceftazidime/avibactam. These findings reveal how epistatic interactions shape the evolution of clinically relevant β-lactamase variants and may help anticipate future resistance trajectories and guide inhibitor design.